Ascendis Pharma A/S (ASND)
Ascendis Pharma A/S
Tuborg Boulevard 12
Hellerup 2900
Denmark
45 70 22 22 44
https://ascendispharma.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 879
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Jan Moller Mikkelsen | President, CEO, Member of Executive Board & Executive Director | N/D | N/D | 1960 |
| Mr. Scott T. Smith | CFO, Executive VP & Member of Executive Board | N/D | N/D | 1974 |
| Ms. Lotte Sonderbjerg | Executive VP, Chief Administrative Officer & Member of the Executive Board | N/D | N/D | 1961 |
| Mr. Michael Wolff Jensen L.L.M. | Executive VP, Chief Legal Officer & Member of the Executive Board | N/D | N/D | 1971 |
| Mr. Mads Bodenhoff | Senior VP of Finance & Principal Accounting Officer | N/D | N/D | N/D |
| Mr. Timothy J. Lee | Senior Director of Investor Relations | N/D | N/D | N/D |
| Mr. Flemming Steen Jensen | Executive Vice President of Product Supply & Quality | N/D | N/D | 1961 |
| Dr. Kennett Sprogoe Ph.D. | Executive VP and Head of Research & Product Development | N/D | N/D | 1979 |
| Dr. Stina Singel M.D., Ph.D. | Executive VP & Head of Clinical Development for Oncology | N/D | N/D | 1974 |
| Mr. Joseph Kelly | Head of U.S. Commercial of Endocrinology | N/D | N/D | 1969 |
Descripción
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Gestión corporativa
La calificación ISS Governance QuickScore de Ascendis Pharma A/S a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
